ARSUF Quote, Financials, Valuation and Earnings

Galapagos NV has a net margin of -- compared to Fagron NV's net margin of -286.67%. Fagron NV's return on equity of 17.38% beat Galapagos NV's return on equity of -16.48%.

Fagron NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of $27.63 which suggests that it could fall by -16.34%. Given that Galapagos NV has higher upside potential than Fagron NV, analysts believe Galapagos NV is more attractive than Fagron NV.

Fagron NV has a beta of -0.038, which suggesting that the stock is 103.849% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.495%.

Fagron NV has a quarterly dividend of $0.39 per share corresponding to a yield of 0%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fagron NV pays 22.18% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. Fagron NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fagron NV quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $83.2M. Fagron NV's net income of -- is lower than Galapagos NV's net income of -$238.4M. Notably, Fagron NV's price-to-earnings ratio is 18.40x while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fagron NV is 1.72x versus 6.87x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -- compared to Fagron NV's net margin of -29.2%. Fagron NV's return on equity of 17.38% beat MDxHealth SA's return on equity of -548.42%.

Fagron NV has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 106.45%. Given that MDxHealth SA has higher upside potential than Fagron NV, analysts believe MDxHealth SA is more attractive than Fagron NV.

Fagron NV has a beta of -0.038, which suggesting that the stock is 103.849% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.

Fagron NV has a quarterly dividend of $0.39 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fagron NV pays 22.18% of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend. Fagron NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fagron NV quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $27.4M. Fagron NV's net income of -- is lower than MDxHealth SA's net income of -$8M. Notably, Fagron NV's price-to-earnings ratio is 18.40x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fagron NV is 1.72x versus 1.63x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to Fagron NV's net margin of -1195.73%. Fagron NV's return on equity of 17.38% beat Nyxoah SA's return on equity of -96.48%.

Fagron NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 151.15%. Given that Nyxoah SA has higher upside potential than Fagron NV, analysts believe Nyxoah SA is more attractive than Fagron NV.

Fagron NV has a beta of -0.038, which suggesting that the stock is 103.849% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fagron NV has a quarterly dividend of $0.39 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fagron NV pays 22.18% of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend. Fagron NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fagron NV quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $2.3M. Fagron NV's net income of -- is lower than Nyxoah SA's net income of -$27.6M. Notably, Fagron NV's price-to-earnings ratio is 18.40x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fagron NV is 1.72x versus 26.52x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -- compared to Fagron NV's net margin of --. Fagron NV's return on equity of 17.38% beat UCB SA's return on equity of 13.88%.

Fagron NV has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Fagron NV has higher upside potential than UCB SA, analysts believe Fagron NV is more attractive than UCB SA.

Fagron NV has a beta of -0.038, which suggesting that the stock is 103.849% less volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.

Fagron NV has a quarterly dividend of $0.39 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.57% to investors and pays a quarterly dividend of $0.79 per share. Fagron NV pays 22.18% of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Fagron NV quarterly revenues are --, which are smaller than UCB SA quarterly revenues of --. Fagron NV's net income of -- is lower than UCB SA's net income of --. Notably, Fagron NV's price-to-earnings ratio is 18.40x while UCB SA's PE ratio is 37.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fagron NV is 1.72x versus 7.26x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.